NASDAQ:RCKT Rocket Pharmaceuticals (RCKT) Stock Price, News & Analysis → The Only Energy Play You Should Be Looking At (From Wealthpin Pro) (Ad) Free RCKT Stock Alerts $21.32 -0.13 (-0.61%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$20.95▼$22.1050-Day Range$20.66▼$27.2552-Week Range$14.89▼$32.53Volume554,881 shsAverage Volume562,361 shsMarket Capitalization$1.94 billionP/E RatioN/ADividend YieldN/APrice Target$52.13 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Rocket Pharmaceuticals alerts: Email Address Rocket Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside144.5% Upside$52.13 Price TargetShort InterestBearish11.00% of Shares Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews Sentiment0.13Based on 14 Articles This WeekInsider TradingSelling Shares$10.41 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.85) to ($1.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.89 out of 5 starsMedical Sector215th out of 928 stocksPharmaceutical Preparations Industry95th out of 437 stocks 3.4 Analyst's Opinion Consensus RatingRocket Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRocket Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Rocket Pharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted11.00% of the outstanding shares of Rocket Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRocket Pharmaceuticals has a short interest ratio ("days to cover") of 14.6, which indicates bearish sentiment.Change versus previous monthShort interest in Rocket Pharmaceuticals has recently increased by 1.52%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRocket Pharmaceuticals does not currently pay a dividend.Dividend GrowthRocket Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRocket Pharmaceuticals has received a 74.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Rocket Pharmaceuticals is -0.81. Previous Next 1.7 News and Social Media Coverage News SentimentRocket Pharmaceuticals has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Rocket Pharmaceuticals this week, compared to 8 articles on an average week. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rocket Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,411,590.00 in company stock.Percentage Held by Insiders31.10% of the stock of Rocket Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.39% of the stock of Rocket Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rocket Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rocket Pharmaceuticals are expected to grow in the coming year, from ($2.85) to ($1.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rocket Pharmaceuticals is -7.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rocket Pharmaceuticals is -7.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRocket Pharmaceuticals has a P/B Ratio of 4.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Rocket Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressDems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.See who it is HERE. About Rocket Pharmaceuticals Stock (NASDAQ:RCKT)Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.Read More RCKT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RCKT Stock News HeadlinesMay 21, 2024 | insidertrades.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) General Counsel Sells $24,470.80 in StockMay 29, 2024 | markets.businessinsider.comRocket Pharma Says EC Granted Orphan Medicinal Product Designation For RP-A601May 29, 2024 | businesswire.comRocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic CardiomyopathyMay 27, 2024 | msn.comDyson exec, Rocket Lab man back Hamilton electric motorbike maker FTN MotionMay 27, 2024 | msn.comRocket Lab's Precision Launch Elevates NASA's Climate Study MissionMay 27, 2024 | news.yahoo.comRocket Park assault leads to arrestMay 27, 2024 | usnews.comChina to Conduct Rocket Launches in Yellow Sea on May 28-31May 26, 2024 | usnews.comJapan Demands North Korea Cancel Satellite Rocket Launch, Spokesperson SaysMay 26, 2024 | barrons.comRocket Sirens Blare In Tel Aviv For First Time In Months: AFPMay 26, 2024 | msn.comHamas Rocket Attack From Gaza Sets off Air Raid Sirens in Tel Aviv for the First Time in MonthsMay 26, 2024 | abcnews.go.comRocket sirens sound in Tel Aviv for the first time in months. Hamas says it fired a barrage from GazaMay 25, 2024 | msn.comRocket Lab launches NASA cubesat to study heat lost from Earth's poles (video)May 23, 2024 | detroitnews.comRocket Mortgage agrees to $3.5 million settlement in overtime pay caseMay 23, 2024 | cbsnews.comPiping plover Sea Rocket spotted on Chicago beachMay 23, 2024 | cbsnews.comNearly-extinct piping plover, Sea Rocket, spotted on Chicago beachMay 10, 2024 | businesswire.comRocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)May 8, 2024 | marketwatch.comLockheed Martin Gets $861.3M U.S. Army Rocket-System PactMay 8, 2024 | usnews.comIsrael Reopens Key Crossing for Aid to Enter Gaza That Was Closed Over Weekend Rocket AttackMay 8, 2024 | markets.businessinsider.comOptimistic Outlook for Rocket Pharmaceuticals with Advancing Pipeline and Solid FinancialsMay 7, 2024 | msn.comRocket Knight Adventures: Re-Sparked Collection - Official Pre-Order TrailerMay 6, 2024 | investorplace.comRCKT Stock Earnings: Rocket Pharmaceuticals Beats EPS for Q1 2024May 6, 2024 | msn.comRocket Pharmaceuticals GAAP EPS of -$0.66 beats by $0.01May 6, 2024 | msn.comRickie Fowler returning for 2024 Rocket Mortgage Classic in Detroit, tickets on sale nowMay 6, 2024 | businesswire.comRocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent ProgressMay 4, 2024 | msn.com3,000+ show up for Cleveland Cavaliers’ watch party at Rocket Mortgage FieldHouse (photos)See More Headlines Receive RCKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today6/01/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RCKT CUSIPN/A CIK1281895 Webwww.rocketpharma.com Phone(609) 659-8001Fax646-224-9585Employees268Year Founded2018Price Target and Rating Average Stock Price Target$52.13 High Stock Price Target$65.00 Low Stock Price Target$39.00 Potential Upside/Downside+144.5%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-245,600,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-53.10% Return on Assets-46.90% Debt Debt-to-Equity Ratio0.04 Current Ratio10.47 Quick Ratio10.47 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.86 per share Price / Book4.39Miscellaneous Outstanding Shares90,780,000Free Float62,549,000Market Cap$1.94 billion OptionableOptionable Beta1.12 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMs. Kinnari Patel M.B.A. (Age 44)Pharm.D., Head of R&D, President & COO Comp: $849.93kMr. Mayo Pujols (Age 54)Chief Technical Officer Comp: $649.71kMr. Raj Prabhakar M.B.A. (Age 49)Chief Business Officer Comp: $619.13kMr. Aaron Ondrey (Age 47)Chief Financial Officer Mr. Martin Louis Wilson J.D. (Age 48)General Counsel, Chief Compliance Officer & Chief Corporate Officer Comp: $149.95kKevin GiordanoDirector of Corporate CommunicationsMs. Isabel Carmona J.D.Chief People OfficerMr. Jonathan Schwartz M.D. (Age 59)Chief Medical & Gene Therapy Officer Comp: $557.79kDr. Gayatri R. Rao J.D.M.D., Senior VP of Clinical Safety & Chief Regulatory OfficerMr. Carlos MartinChief Commercial Operations & Revenue OfficerMore ExecutivesKey CompetitorsArcus BiosciencesNYSE:RCUSDicerna PharmaceuticalsNASDAQ:DRNAAurinia PharmaceuticalsNASDAQ:AUPHHeron TherapeuticsNASDAQ:HRTXY-mAbs TherapeuticsNASDAQ:YMABView All CompetitorsInsiders & InstitutionsComerica BankSold 23,500 shares on 5/17/2024Ownership: 0.589%Ikarian Capital LLCSold 92,630 shares on 5/17/2024Ownership: 0.327%Janus Henderson Group PLCBought 1,656,111 shares on 5/16/2024Ownership: 2.871%Gaurav ShahSold 9,790 sharesTotal: $228,596.50 ($23.35/share)Martin WilsonSold 1,048 sharesTotal: $24,470.80 ($23.35/share)View All Insider TransactionsView All Institutional Transactions RCKT Stock Analysis - Frequently Asked Questions Should I buy or sell Rocket Pharmaceuticals stock right now? 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RCKT shares. View RCKT analyst ratings or view top-rated stocks. What is Rocket Pharmaceuticals' stock price target for 2024? 9 brokers have issued 1-year target prices for Rocket Pharmaceuticals' stock. Their RCKT share price targets range from $39.00 to $65.00. On average, they predict the company's stock price to reach $52.13 in the next year. This suggests a possible upside of 144.5% from the stock's current price. View analysts price targets for RCKT or view top-rated stocks among Wall Street analysts. How have RCKT shares performed in 2024? Rocket Pharmaceuticals' stock was trading at $29.97 at the beginning of 2024. Since then, RCKT shares have decreased by 28.9% and is now trading at $21.32. View the best growth stocks for 2024 here. When is Rocket Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our RCKT earnings forecast. How were Rocket Pharmaceuticals' earnings last quarter? Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) issued its quarterly earnings data on Monday, May, 6th. The biotechnology company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.01. During the same period in the prior year, the firm earned ($0.73) earnings per share. What ETFs hold Rocket Pharmaceuticals' stock? ETFs with the largest weight of Rocket Pharmaceuticals (NASDAQ:RCKT) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Tema Cardiovascular and Metabolics ETF (HRTS), Harbor Health Care ETF (MEDI), Franklin Genomic Advancements ETF (HELX) and Harbor Disruptive Innovation ETF (INNO).Putnam BioRevolution ETF (SYNB) and What other stocks do shareholders of Rocket Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA). Who are Rocket Pharmaceuticals' major shareholders? Rocket Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.92%), Westfield Capital Management Co. LP (4.39%), Price T Rowe Associates Inc. MD (3.24%), Janus Henderson Group PLC (2.87%), Bamco Inc. NY (1.09%) and Russell Investments Group Ltd. (0.74%). Insiders that own company stock include David P Southwell, Gaurav Shah, Gotham Makker, John Militello, Jonathan David Schwartz, Kinnari Patel, Mark Andrew White, Martin Wilson and Rtw Investments, Lp. View institutional ownership trends. How do I buy shares of Rocket Pharmaceuticals? Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RCKT) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rocket Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.